BRD4 was reported to recruit MED1 and p65 to form super-enhancers, and a BRD4 inhibitor was reported to disrupt super-enhancers and decrease the tumorigenic potential of cancer stem cells in head and neck squamous cell carcinoma. This evidence concerns the gene BRD4 and cancer.